NPPB and hydrops fetalis: In the PROVE-HF(Prospective Study of Biomarkers, Symptom Improvement and Ventricular RemodelingDuring Entresto Therapy for Heart Failure Study) trial, a decrease in circulatinglevels of NT-proBNP correlated with improved markers of cardiac function andvolume in patients with HFrEF treated with S/V, suggesting reverse cardiacremodelling as its possible mechanism of benefit [54].